BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29

BERKELEY, Calif., and VANCOUVER, British Columbia, March 31, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has been selected to present at the 2020 ASCO Annual Meeting, a virtual event held during the dates of the originally …

BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic

• Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic. • Clinical and immune activity of Bria-IMT™, alone or in combination with checkpoint inhibitors, KEYTRUDA® and INCMGA00012, in advanced breast cancer will be presented at the American Association for …

BriaCell to Present Clinical and Immune Activity at AACR Annual Meeting

• Clinical and immune activity of BriaCell’s lead candidate, Bria-IMT™, alone or in combination with checkpoint inhibitors, KEYTRUDA® and INCMGA00012, in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 28, 2020. • Clinical activity and potential correlation with immune activity and patient subsets will be …

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa Combination Study of Bria-IMT™

· Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University. · Merck to provide KEYTRUDA® for use in the combination study. · The Investigator Grant validates and will build on the encouraging preliminary data from BriaCell’s …

BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: • Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.); • Bria-IMT™ in combination with INCMGA00012 (by Incyte Corporation). BERKELEY, Calif., and VANCOUVER, British Columbia, January 28, 2020 — BriaCell …

BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine

BERKELEY, Calif., and VANCOUVER, British Columbia, January 22, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announced today that it will present at the “Frontiers in Academic Pathology” symposium, hosted by the Icahn School of Medicine at Mount Sinai, to …

BriaCell Provides Update on Remarkable Responder

• Patient initially identified September 19, 2019 as a Remarkable Responder; • Patient has continued to experience a highly remarkable reduction in tumors that had metastasized to areas outside of the breasts; • A metastasized tumor behind the left eye orbital region, which had pushed the eye forward from the skull, has now completely disappeared; …

BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade

• BriaCell has identified a patient population Biomarker with high rate of clinical benefit from the treatments based on ‘Breast Cancer Grade’; • Breast Cancer Grade correlates with response in both studies of monotherapy (Bria-IMT™ alone), and combination study of Bria-IMT™ with KEYTRUDA®; • New predicative Biomarker capability is complimentary to BriaCell’s HLA-matching hypothesis. BERKELEY, …

BriaCell Completes Share Consolidation

BERKELEY, Calif., and VANCOUVER, British Columbia, January 2, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has completed its previously announced consolidation of the common shares of the Company at a ratio of three …

BriaCell Therapeutics Corp. Announces Share Consolidation

BERKELEY, Calif., and VANCOUVER, British Columbia, December 24, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that its Board of Directors has approved a consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on …